期刊文献+

冠状动脉粥样硬化性心脏病患者血清总胆红素水平与外周动脉疾病的相关性研究 被引量:2

Relation between total serum bilirubin and peripheral artery disease in patients with coronary atherosclerotic heart disease
下载PDF
导出
摘要 目的探讨冠状动脉粥样硬化性心脏病(冠心病)患者血清总胆红素水平与外周动脉疾病(PAD)的相关性。方法收集2017年1月至2018年1月入住山西省心血管病医院的162例冠心病患者的病历资料,根据患者血清总胆红素检测结果分为总胆红素升高(17.2~46.2μmol/L)组(观察组,41例)和总胆红素正常(1.7~17. 1μmol/L)组(对照组,121例)。比较2组患者性别、年龄、吸烟史和合并高血压病、糖尿病比例,血常规和血生化指标和左心室射血分数水平,以及PAD的发生率。比较PAD与非PAD患者总胆红素水平,分析冠心病患者发生PAD的危险因素。结果观察组男性比例和血红蛋白、丙氨酸转氨酶、估算肾小球滤过率水平均高于对照组[80.5%(33/41)比71.1%(86/121)、(139±10)g/L比(130±12)g/L,(22±5)mmol/L比(18±5)mmol/L、(62±10) ml/(min·1. 73 m2)比(60±14)ml/(min·1.73 m^2)],年龄、血小板计数和PAD比例均低于对照组[56(48,67)岁比57(51,64)岁、(19±3)×10~9/L比(21±3)×10~9/L、46. 3%(19/41)比55.4%(67/121)],差异均有统计学意义(均P<0.05)。PAD患者(86例)血清总胆红素水平低于非PAD患者(76例)[11. 2(5. 8,18. 6)μmol/L比17. 2(8. 9,27.4)μmol/L],差异有统计学意义(P <0.001)。校正混杂因素后多元Logistic回归分析发现,估算肾小球滤过率(比值比=0.76,95%置信区间:0.62~0. 86,P=0. 002)、总胆红素水平(比值比=0. 74,95%置信区间:0. 56~0. 84,P<0. 001)为PAD发生的独立预测因素。结论血清总胆红素水平与冠心病患者PAD患病率相关,可作为冠心病患者发生PAD的独立预测因子。 Objective To explore the relation between serum bilirubin and peripheral artery disease (PAD)in patients with coronary atheroselerotie heart disease (CHD).Methods A total of 162CHD patients admitted to Shanxi Cardiovascular Hospital from January 2017to January 2018were divided into elevated total bilirubin group(observation group,17.2-46.2μmol/L,n =41)and no,anal total bilirubin group (eontrol group, 1.7-17.1μmol/L,n =121).Sex,age,smoking history,hypertension,diabetes,blood routine and bioehemistry indexes,left ventricular ejection fraction and the prevalence rate of PAD were recorded.Serum bilirubin level was analyzed between PAD and non-PAD patients.Risk factors of PAD were analyzed by Logistic regression.Results Male ratio,hemoglobin level,alanine aminotransferase level and estimated glomerular filtration rate (eGFR)in the observation group were higher than those in the control group [80.5%(33/41)vs 71.1%(86/121),(139±10)g/Lvs (130±12)g/L,(22±5)mmol/Lvs (18±5)mmol/L,(62±10)ml/(min ±1.73m2)vs (60± 14)ml/(min·1.73m^2)];age,platelet count and PAD ratio in the observation group were lower than those in the control group[56(48,67)years vs 57(51,64)years,(19±3)×10^9/L vs (21±3)×10^9/L,46.3%(19/41)vs 55.4%(67/121)](all P <0.05).Serum bilirubin level in PAD patients (n =86)was lower than that in non-PAD patients (n=76)[11.2(5.8,18.6)μmol/L vs 17.2(8.9,27.4)μmol/L ](P <0.001).After adjustment of confounding factors,Logistic regression showed that eGFR (odds ratio =0.76,95%confidence interval:0.62- 0.86,P =0.002)and total bilirubin level(odds ratio =0.74,95%confidence interval:0.56-0.84,P <0.001) were independent predictive factors of PAD.Conclusion Serum bilirubin level can be a independent predictor of PAD in CHD patients.
作者 王飞 杨滨 Wang Fei;Yang Bin(Department of Cardiology,Shanxi Cardiovascular Hospital,Shanxi Institute of Cardiovascular Disease,Taiyuan 030024,China)
出处 《中国医药》 2018年第12期1796-1799,共4页 China Medicine
基金 山西省科学技术厅青年科技研究基金(2015021174)~~
关键词 冠状动脉粥样硬化性心脏病 总胆红素 外周动脉疾病 踝肱指数 Coronary atherosclerotie heart disease Serum bilirubin Peripheral artery disease Ankle brachial index
  • 相关文献

参考文献3

二级参考文献42

  • 1李国宏.冠心病患者胆红素、尿酸、血脂水平及其临床意义[J].临床和实验医学杂志,2010,9(6):425-426.
  • 2Keeley EC,Hillis LD. Primary PCI for myocardial infarction with ST-segment elevation[J].New England Journal of Medicine,2007,(01):47-54.
  • 3Brosh D,Assali AR,Mager A. Effect of no-reflow during primary percutaneous coronary intervention for acute myocardial infarction on six-month mortality[J].American Journal of Cardiology,2007,(04):442-445.
  • 4Niccoli G,Burzotta F,Galiuto L. Myocardial no-reflow in humans[J].Journal of the American College of Cardiology,2009,(04):281-292.doi:10.1016/j.jacc.2009.03.054.
  • 5Guasti L,Dentali F,Castiglioni L. Neutrophils and clinical outcomes in patients with acute coronary syndromes and/or cardiac revascularisation.A systematic review on more than 34,000 subjects[J].Thrombosis and Haemostasis,2011,(04):591-599.
  • 6Meissner J,Irfan A,Twerenbold R. Use of neutrophil count in early diagnosis and risk stratification of AMI[J].American Journal of Medicine,2011,(06):534-542.
  • 7Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS),European Association for Percutaneous Cardiovascular Interventions (EAPCI),Wijns W. Guidelines on myocardial revascularization[J].European Heart Journal,2010,(20):2501-2555.
  • 8Jaffe R,Charron T,Puley G. Microvascular obstruction and the no-reflow phenomenon after percutaneous coronary intervention[J].Circulation,2008,(24):3152-3156.doi:10.1161/CIRCULATIONAHA.107.742312.
  • 9Lee CH,Tai BC,Low AF. Angiographic no-reflow and six-month mortality in elderly (》/= 75 years old) Asian patients undergoing primary percutaneous coronary intervention:A single center experience from 1998 to 2007[J].Acute Card Care,2010,(02):63-69.
  • 10Ndrepepa G,Tiroch K,Fusaro M. 5-year prognostic value of no-reflow phenomenon after percutaneous coronary intervention in patients with acute myocardial infarction[J].Journal of the American College of Cardiology,2010,(21):2383-2389.

共引文献11

同被引文献12

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部